Literature DB >> 11182372

Treatment with human parathyroid hormone (1-34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fascicularis).

C P Jerome1, D B Burr, T Van Bibber, J M Hock, R Brommage.   

Abstract

A key feature of postmenopausal osteoporosis is the loss of trabecular bone mass and connectivity. The current study focuses on these parameters in the assessment of long-term (12 and 18 months) parathyroid hormone (PTH) therapy and its withdrawal (6 months) in the ovariectomized cynomolgus monkey (Macaca fascicularis), a well-characterized model for bone changes associated with postmenopausal osteoporosis. We used static and dynamic histomorphometric parameters to assess the amount and architecture of cancellous bone in four clinically important sites for osteoporotic fractures, including the lumbar vertebra, femoral neck, distal radius, and iliac crest. Recombinant human PTH(1-34) was administered daily to two groups for 18 months at 1.0 microg/kg per day (n = 19) and 5.0 microg/kg per day (n = 21). To study the effects of PTH withdrawal, two groups were administered PTH(1-34) daily for 12 months at 1.0 microg/kg per day (n = 20) and 5.0 microg/kg per day (n = 20), followed by daily administration of vehicle for 6 months. Sham-ovariectomized and ovariectomized (ovx) groups each received daily injections of vehicle for 18 months. Treatment with PTH had minimal effects on bone formation rates at the timepoints studied, but markedly increased cancellous bone volume relative to ovx monkeys in iliac crest biopsies at 6 and 15 months, as well as in terminal specimens of lumbar vertebrae, femoral neck, and distal radius after 18 months. At all sites, PTH significantly improved trabecular architecture, as evidenced by increased trabecular number (Tb.N) and decreased trabecular separation (Tb.Sp), with no significant change in trabecular thickness (Tb.Th). The mechanism of these structural changes is suggested by qualitative observations of trabecular tunneling observed in the iliac crest and vertebra. Longitudinal tunneling of thickened individual trabeculae is hypothesized to convert them into multiple trabeculae, resulting in a normalization of Tb.Th, but an increase in Tb.N. A significant positive effect on cancellous bone volume was still apparent after a 3-6 month withdrawal period following 12 months of PTH treatment in the iliac crest, vertebra, and femoral neck. Corresponding increases in Tb.N and decreases in Tb.Sp also remained significant after PTH withdrawal at these three sites. The distal radius was relatively insensitive to PTH treatment or its withdrawal, compared with the other bones. In summary, PTH therapy dramatically improved cancellous bone mass and architecture in both axial and appendicular sites.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11182372     DOI: 10.1016/s8756-3282(00)00430-0

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  38 in total

1.  Changes in trabecular and cortical bone microarchitecture at peripheral sites associated with 18 months of teriparatide therapy in postmenopausal women with osteoporosis.

Authors:  H M Macdonald; K K Nishiyama; D A Hanley; S K Boyd
Journal:  Osteoporos Int       Date:  2010-05-11       Impact factor: 4.507

2.  Engraftment and bone mass are enhanced by PTHrP 1-34 in ectopically transplanted vertebrae (vossicle model) and can be non-invasively monitored with bioluminescence and fluorescence imaging.

Authors:  Blake Eason Hildreth; Michelle M Williams; Katarzyna A Dembek; Krista M Hernon; Thomas J Rosol; Ramiro E Toribio
Journal:  Transgenic Res       Date:  2015-08-14       Impact factor: 2.788

3.  Long-term stability and in vitro release of hPTH(1-34) from a multi-reservoir array.

Authors:  Elizabeth R Proos; James H Prescott; Mark A Staples
Journal:  Pharm Res       Date:  2008-06       Impact factor: 4.200

4.  Parathyroid hormone analogues in the therapy of osteoporosis.

Authors:  Markus Müller; Peter Pietschmann
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

Review 5.  Parathyroid hormone as an anabolic skeletal therapy.

Authors:  Mishaela R Rubin; John P Bilezikian
Journal:  Drugs       Date:  2005       Impact factor: 9.546

6.  Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys.

Authors:  C Jerome; M Missbach; R Gamse
Journal:  Osteoporos Int       Date:  2011-02-10       Impact factor: 4.507

7.  Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys.

Authors:  C Jerome; M Missbach; R Gamse
Journal:  Osteoporos Int       Date:  2011-03-05       Impact factor: 4.507

8.  Implantable multireservoir device with stimulus-responsive membrane for on-demand and pulsatile delivery of growth hormone.

Authors:  Seung Ho Lee; Huiyan Piao; Yong Chan Cho; Se-Na Kim; Goeun Choi; Cho Rim Kim; Han Bi Ji; Chun Gwon Park; Cheol Lee; Chong In Shin; Won-Gun Koh; Young Bin Choy; Jin-Ho Choy
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-23       Impact factor: 11.205

9.  Full length parathyroid hormone (1-84) in the treatment of osteoporosis in postmenopausal women.

Authors:  Esteban Jódar-Gimeno
Journal:  Clin Interv Aging       Date:  2007       Impact factor: 4.458

10.  Effects of PTH treatment on tibial bone of ovariectomized rats assessed by in vivo micro-CT.

Authors:  J E M Brouwers; B van Rietbergen; R Huiskes; K Ito
Journal:  Osteoporos Int       Date:  2009-03-05       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.